Breve descripción
The purpose of the PrisMN Phase 2 study is to evaluate the safety and efficacy of three dose regimens of budoprutug in subjects with PMN.
Médico del ensayo / Coordinador del estudio
Elizabeth Nguyen, MD
Estimated Enrollment
45
Estimated End Date
Oct-27
Trial is for people with
primary membranous nephropathy (PMN) who are anti-PLA2R antibody positive
Study Goal
The PrisMN study seeks to evaluate the safety, tolerability, pharmacodynamics (PD), and preliminary efficacy, of budoprutug, as well ...
What is involved for the patient?
Participants will be asked to allow PrisMN researchers to access medical history to confirm eligibility to participate. They will be ...
About the drug or intervention
Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete ...